Herombopag promotes platelet engraftment and decreases platelet transfusion after allogeneic hematopoietic stem cell transplantation

Abstract

The delayed platelet engraftment associated with allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a common complication and often results in increased transplant-related complications. A single-center, prospective, investigator-initiated pilot study was conducted to explore whether herombopag, a second generation thrombopoietin-receptor agonist, would promote platelet engraftment after allo-HSCT. Between 2/2022 and 06/2022, 17 individuals (median age 39; range 15-58 years) with hematological malignancies were enrolled. Herombopag was given for a median of 22 (range 14-61) days at a dose of 7.5 mg/d. The median time to neutrophil >500/μl was 11 (range 9-19) days. The median time to platelet >20 000/ μl and >50 000/μl was 13 (range 8-22), and 20 (range 14-45) days, respectively.

Knowledge map of thrombopoietin receptor agonists: A bibliometric analysis

“…Another real-world study revealed the efficacy of eltrombopag in providing a rapid, sustained response that improves haematopoietic function in PGF patients [ 44 ]. Avatrombopag [ 45 , 46 ], hetrombopag [ 47 ], and romiplostim [ 48 ] have all been reported to improve platelet engraftment post-HSCT. A recent systematic review and meta-analysis has concluded that eltrombopag could provide an effective treatment option for PGF with an acceptable toxicity profile [ 49 ].…”